Auro Laboratories Limited
AUROLAB.BO
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.47B
Close$
Share Statistics
| Market cap | $1.47 Billion |
|---|---|
| Enterprise Value | $1.47 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $5.68 |
| Beta | 0.05 |
| Outstanding Shares | 6,223,809 |
Return
| Return on Equity | 10.11% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 31.46 |
|---|---|
| PEG | -2.88 |
| Price to Sales | 3.81 |
| Price to Book Ratio | 3.04 |
| Enterprise Value to Revenue | 4 |
| Enterprise Value to EBIT | 13.08 |
| Enterprise Value to Net Income | 31 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Auro Laboratories Limited
72 employees
CEO: Sharat Sahadeolal Deorah Based in Mumbai, India, Auro Laboratories Ltd. commenced operations on May 26, 1989. The company primarily deals in active pharmaceutical ingredients (APIs) and also supplies bulk drugs.